Preclinical trial results on Xeltis’ restorative aortic valve and its assessment model showed an excellent hemodynamic performance and a positive safety profile. Over 50 implants have been performed to date and current results demonstrate stable hemodynamic performance at three and six months from implantation. The trial results illustrate the potential of Endogenous Tissue Restoration (ETR) for aortic valve replacement applications.
The latest trial outcomes have been presented by leading US cardiac surgeon, Dr Gregory Fontana, at The International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) annual meeting today. Initial results from the same study had been recently presented at EuroPCR meeting in Paris last May.
“Xeltis restorative valves have potential to help overcome chronic inflammation, a primary cause of complications and valve degeneration, which is generally associated with existing animal-derived valve replacement options”, explained Dr Fontana, National Medical Director for Cardiovascular Research, Hospital Corporation of America, Director and Chairman of Cardiothoracic Surgery, CardioVascular Institute, Hospital and Medical Center, Los Robles Medical Centre, Thousand Oaks, California. “Valve durability is essential to enable younger and lower risk patients to access transcatheter aortic valve replacement (TAVR)” he added.
ISMICS annual meeting focuses on innovation, technologies and techniques in cardiothoracic and cardiovascular and vascular surgery and it is taking place 7-10 June in Rome, Italy.
